Wenshen Zhuanggu formula (WSZG) is a traditional Chinese medicine used as an adjuvant for the prevention of bone metastases in breast cancer patients. In this study we investigated the efficacy of WSZG in preventing bone metastases and the potential mechanisms in a mouse xenograft model of breast cancer bone metastases. This model was established by injection of human MDA-MB-231BO-Luc breast cancer cells alone or a mixture of the cancer cells with bone marrow-derived mesenchymal stem cells (BMSCs) into left ventricle of the heart in female nude mice. Then the mice were treated with WSZG (3.25, 6.5 or 13.0 mg·kg -1 ·d -1
Introduction
The incidence of breast cancer among women has rapidly increased worldwide. Breast cancer cells spread from the primary site to distant organs, such as bones, lungs, and liver [1] . Bones are the most common sites of breast cancer metastases. Approximately 65% to 75% of advanced breast cancer patients eventually develop bone metastases, which remain the leading cause of death and have a five-year survival rate of only 20% [2] . Bone metastases are a major clinical concern and can cause pain, pathologic fractures, hypercalcemia, spinal cord compression, and other bone-related events. Bone metastases severely affect the life quality of patients. Routine treatments for breast cancer with bone metastases include radiotherapy, chemotherapy, and bisphosphonates. These therapies effectively reduce the frequency of bone-related events, inhibit cancer-mediated bone resorption, and reduce pain in bonemetastatic breast cancer patients [3] . However, these therapies have significant side effects, such as induction of arthralgias and osteonecrosis of the jaw. In China, the combination of modern western therapies and traditional Chinese medicine (TCM) is a common approach to treat breast cancer with bone metastases. As an important complementary therapy, Chinese herbal medicine can effectively resolve breast lumps, alleviate bone pain, minimize the adverse events of chemotherapy, and improve the overall health and well-being of cancer patients [4] .
The Wenshen Zhuanggu formula (WSZG), a TCM prescription, has been used extensively as an adjuvant to treat patients with breast cancer bone metastases in Longhua Hospital. WSZG is composed of the herbs Fructus psoraleae (Bu-GuZhi in Chinese; Psoralea fruit, Psoralea corylifolia L), Fructus cnidii (She-Chuang-Zi in Chinese; Cnidium fruit, Cnidium monnieri L), and Aconiti lateralis radix praeparata (Fu-Zi in Chinese; processed aconite root, Aconitum carmichaelii Debx). A retrospective cohort study on 48 patients with breast cancer bone metastases confirmed that WSZG could prevent the development of bone metastases and improve the quality of life of the patients [5] . In a previous experimental study, WSZG significantly reduced the frequency of bone metastases and mitigated osteolytic lesions in nude mice with breast cancer bone metastases [6] . The underlying cellular and molecular mechanisms of breast cancer bone metastases remain complicated and unclear. Recently, increasing focus has been directed to the contribution of bone marrow-derived mesenchymal stem cells (BMSCs). As adult progenitor cells, BMSCs can differentiate into adipocytes, osteocytes, and chondrocytes under special conditions and promote stromal tissue renewal [7] . Many studies have affirmed that BMSCs are actively involved in breast carcinoma bone metastatic processes. On the one hand, BMSCs in the bone marrow facilitate the multiplication and morphology of breast cancer cells in the bone through paracrine factors and the secretion of chemotactic cytokines [8] . On the other hand, BMSCs in the circulating blood are recruited to the site of in situ breast tumor and stimulate the growth of tumors and the frequency of bone metastasis via the interaction between BMSCs and breast cancer cells [9] . In our previous study, we found that WSZG-containing serum exerts an anti-metastatic activity against MDA-MB-231BO breast cancer cells by preventing the interaction between BMSCs and breast cancer cells in vitro [10] . Therefore, in the present study, we further explored the pharmacological activities and potential mechanisms of WSZG in an animal model of breast cancer bone metastases.
Materials and methods
Plant materials and preparation of WSZG Fructus psoraleae, Fructus cnidii, and Aconiti lateralis radix praeparata were purchased from Shanghai Kang Qiao Chinese Cut Crude Drug Co Ltd (Shanghai, China, Lot 12615) and authenticated by Prof Zhi-li ZHAO from the Department of Pharmacognosy, Shanghai University of TCM. Morphological, microscopic, and phytochemical identifications were performed according to the Pharmacopoeia of the People's Republic of China (2010 edition). Herbarium voucher specimens were deposited at Longhua Hospital, which is affiliated with Shanghai University of TCM, with voucher numbers as follows: BGZ-1207081 for Fructus psoraleae, SCZ-1207082 for Fructus cnidii, and FZ-1207083 for Aconiti lateralis radix praeparata.
A WSZG extract was prepared according to our previous method [10] . Briefly, Fructus psoraleae, Fructus cnidii, and Aconiti lateralis radix praeparata were mixed at a ratio of 5:5:3. The mixture was immersed in 55% ethanol (1:10, w/v) for 4 h and refluxed for 1.5 h. After filtration, the residue was refluxed again with 55% ethanol (1:8, w/v) for 1 h and filtered. Thereafter, the two decoctions were combined and concentrated with a vacuum to a final concentration of 2 g/mL. The ethanol in the extract was volatilized completely. Quality assurance for the WSZG extract was carried out by quantifying three marker compounds with high-performance liquid chromatography (HPLC). The results of HPLC analysis were the same as described in our previous in vitro experiment. The content of psoralen, isopsoralen, and osthole in the extract was 15.3, 11.6, and 25.2 mg/g, respectively [10] . 
Chemicals and reagents

Cell culture
Human fetal BMSCs (Cat No HUXMF-01001) were obtained from Cyagen Bioscience (Guangzhou) Inc (Guangzhou, China). These BMSCs are positive for CD29, CD44, and CD105 but negative for CD34 and CD45. Human breast cancer MDA-MB-231BO cells were donated by Dr Toshiyuki YONEDA (Osaka University). These cells stably express the firefly luciferase (Luc) reporter gene. Both cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL of penicillin, 100 μg/mL of streptomycin, and 1% L-glutamine in a humidified atmosphere of 5% CO 2 and 95% air at 37 °C.
Animals
Female athymic nude mice (BALB/c, 6-8 weeks, weighing 18.0±1.3 g) were obtained from Shanghai Experimental Animal Center of Chinese Academy of Sciences and housed in a 12 h dark/light cycle environment at a temperature of 22±2 °C and relative air humidity of 45%-55%. Food and water were provided ad libitum. All animals received humane care in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Research Ethics Committee of Shanghai University of TCM (Permit Number: 12010). All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were exerted to minimize suffering.
Xenograft model of breast cancer bone metastases and drug treatment A xenograft model of bone metastases was established as previously described [11] . Briefly, after anaesthetization with 75 mg/kg of pentobarbital sodium, the mice were injected with Luc-labeled cancer cells alone (0.5×10 6 cells per mouse, suspended in 100 μL of phosphate-buffered saline) or mixed with BMSCs (0.5×10 6 cells per mouse, 1:1 mixture) into the left ventricle of the heart. The development and growth of bone metastases in the mice were monitored weekly through bioluminescent imaging. A week after modeling, 48 animals were randomly divided into the following six groups (n=8): model A group (injection of cancer cells alone, ig saline), model B group (co-injection of cancer cells and BMSCs, ig saline), three dosages of WSZG groups (co-injection of cancer cells and BMSCs, ig 3.25, 6.5, and 13.0 g/kg of WSZG), and zoledronic acid (ZA) group (co-injection of cancer cells and BMSCs, ip 100 µg/kg of ZA solution). The animals were administered WSZG once per day and the ZA solution once per week continuously for four weeks. Additionally, the eight mice used as the normal control group were intracardially injected with saline instead of cancer cells. At the experimental endpoint, all mice were euthanized. Bone fragments were excised, fixed in 4% paraformaldehyde overnight, and stored at -80 °C until further analysis.
In vivo bioluminescent imaging (BLI)
Bioluminescent imaging was performed with an in vivo optical imaging system (IVIS 200; Xenogen Corp.) following the procedure of Dragulescu-Andrasi et al [12] . All animals were anesthetized with isoflurane gas (2% isoflurane in oxygen, 1 L/min) during the imaging procedure. Each animal was imaged for 8-10 min after intraperitoneal injection of 100 μL of D-luciferin solution (15 mg/mL), and a bioluminescence image was then acquired. Signals were quantified with the Living Image software (Xenogen Corp) by drawing a circular ROI around each bioluminescent source. The results are reported as total photon flux within an ROI in photons per second (photon· s
Histology and tartrate-resistant acidic phosphatase (TRAP) staining Through BLI and radiography, tumor metastatic regions of the spine and limbs were selected from the untreated, WSZG, and ZA-treated groups. Bone fragments were excised, fixed in 4% polyformaldehyde for 48 h, and decalcified in 10% EDTA for 10-14 d. The decalcified bone tissues were embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). TRAP staining was performed using an acid phosphatase kit (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. TRAP-positive osteoclasts existing in trabecular bone surfaces were identified as previously described [13] . Histologic changes were observed, and the number of osteoclasts in 5 consecutive fields of one section per specimen at 40×mag-nification were counted under a light microscope [14] .
Micro-CT imaging
The metastatic lesions of mouse spines were dissected and fixed in 4% paraformaldehyde for 2 h. Then, the samples were scanned by a Quantum FX micro CT Imaging System (PerkinElmer, Inc, USA) at high resolution (36 μm per pixel) using a voltage of 90 kV and a current of 88 μA. Each CT scan was completed in approximately 14 min. Three-dimensional (3D) reconstruction images were acquired by Caliper Analyze and 3D Viewer software (PerkinElmer, Inc, USA).
Immunohistochemistry assay (IHC)
Immunohistochemical staining was performed with a twostep EnVision/HRP system (Dakocytomation, Denmark) according to the manufacturer's instructions. Briefly, decalcified bone sections were blocked with 10% normal goat serum for 30 min and subsequently incubated with primary antibodies to CCL5 (1:100 dilution), CCR5 (1:400 dilution), IL-17B (1:300 dilution), and IL-17BR (1:200 dilution) for 2 h at room temperature. After being washed three times with phosphatebuffered saline, the slides were incubated for 30 min at 37 °C with the EnVision complex (a large number of secondary antibodies and horseradish peroxidase coupled to a dextran backbone). Diaminobenzidine hydrochloride (DAB) was used as the chromogen. The expression of CCL5, CCR5, IL-17B, and IL-17BR was quantitatively evaluated with an Olympus BH2 microscope with a computer-aided image analysis system. The digital images were archived by a digital camera (Nikon 4500, Tokyo, Japan). The positive area and optical density (OD) of positive cells were determined by measuring three randomly selected microscopic fields for each slide. The IHC index was defined as the average integral optical density (AIOD) (AIOD=positive area×OD/total area).
Real-time quantitative polymerase chain reaction (PCR)
The total RNA of bone tissues was extracted with TRIzol and reverse transcribed to cDNA by using PrimeScript ® RT reagent kits according to the manufacturer's instructions. The realtime polymerase chain reaction (PCR)-specific primers were 5'-GGAGTATTTCTACACCAGCAGCAAG-3' (forward) and 5'-GGCTAGGACTAGAGCAAGCAATGAC-3' (reverse) for CCL5, 5'-GCAGAAGCTCCAAGAGATGAGGA-3' (forward) and 5'-A GCCATCTGGAAAGTGTGACTGAA-3' (reverse) for CCR5, 5'-GAGCCAGCCAAGAAGAAATGTGA-3'(forward) and 5'-GGATTCACGCAACCCAAACATAG-3' (reverse) for IL-17B, and 5'-GATGGTCCAACACACACTCACTC-3' (forward) and 5'-GCAGATCTTGGTGGCCTTC-3' (reverse) for IL-17BR. GAPDH was used as a control to normalize the relative gene expression level. PCR was performed using the following protocol: 95 °C (30 s), 95 °C (5 s), and 60 °C (30 s) in a total of 40 cycles. Real-time PCR was conducted with the ABI Prism 7500 (Applied Biosystems, USA) sequence detection system. The data were analyzed with ABI Step One software version 2.1 (Applied Biosystems, USA). Values are expressed as the cycle threshold (CT) and identified by three indepen-dent experiments, each of which was performed in triplicate. The fold change in the expression of the detected genes was calculated with the 2 -ΔΔCT method [15] .
Western blotting
Bone tissues were lysed with RIPA buffer containing the protease inhibitor PMSF, and total protein was collected through centrifugation (14 000×g for 5 min at 4 °C). The samples (30 μg) were separated with 10%-15% SDS-PAGE gels and transferred onto PVDF membranes (0.45 μm). After blocking with 5% non-fat dry milk, the membranes were incubated with the primary antibodies for CCL5 (1:500), CCR5 (1:100), IL-17B (1:500), IL-17BR (1:100), and β-actin (1:1000) overnight at 4 °C. The membranes were washed three times and incubated with the appropriate HRP-conjugated secondary antibody (1:10000) for 2 h at room temperature. Blots were subsequently visualized using ECL substrates. The images were digitalized with a gel imaging system (Alpha Innotech Corp, USA). β-Actin was used as an internal reference.
Statistics
The data are presented as the mean±SEM. Analysis of variance (ANOVA) was used for multiple comparisons, and Fisher's LSD test or the Games-Howell test was used for the comparison of two mean values. A value of P<0.05 was considered statistically significant. Effect of WSZG on the incidence and intensity of bone metastasis induced by MDA-MB-231BO+BMSC co-injection in nude mice Four weeks after treatment with drugs or saline, the bioluminescent signals in each group were detected and quantified by in vivo BLI. As shown in Figure 2A , the BLI signals in WSZG and ZA-treated groups were relatively weaker than those in the two model groups. Similar to the BLI observation, treatment with WSZG and ZA significantly reduced the total tumor burden, which was determined by the radiance of tumor luminescence compared with the model B group (P<0.05 or P<0.01, Figure 2B) . Furthermore, the model B group exhibited a higher frequency of bone metastases than the model A group. WSZG and ZA significantly reduced the number of bone metastatic sites (P<0.05 or P<0.01, Figure 2C ).
Results
BMSCs
Effect of WSZG on metastatic bone lesions induced by MDA-MB-231BO+BMSC co-injection in nude mice
As shown in the 3D micro-CT scanning image of tumor-bearing spines in different groups, MDA-MB-231BO breast cancer cells clearly caused osteolytic bone lesions, and BMSCs further aggravated the severity of bone erosion. Treatment with WSZG or ZA markedly reduced the extent of bone lesions when compared to the model groups ( Figure 3A) . H&E staining revealed extensive tumor cell infiltrations and partial bone destruction in bone metastatic tissues from the model mice. By contrast, treatment with WSZG or ZA distinctly alleviated the extent of tumor cell infiltrations in bone tissues ( Figure 3B ). To confirm the effect of WSZG on the number of osteoclasts, spine sections were stained with TRAP. As shown in Figure  3C , TRAP-positive multinucleated cells located at the trabecular bone surface were considered osteoclasts. Compared to normal mice, model mice had a significantly higher number of osteoclasts in the region with metastatic bone lesions (P<0.01). WSZG (6.5, and 13.0 g·kg -1 ·d -1 ) and ZA treatment effectively decreased the number of osteoclasts in the region with metastatic bone lesions compared to model groups (P<0.05 or P<0.01). Additionally, there was no difference in the number of osteoclasts between model A and model B groups (P>0.05).
Effect of WSZG on CCL5/CCR5 and IL-17B/IL-17BR mRNA expres sion in bone metastatic tissues Growing evidence demonstrates that the CCL5/CCR5 and IL-17B/IL-17BR axis may be linked to breast cancer progression induced by the interaction between BMSCs and breast cancer cells [16] [17] [18] [19] . Thus, we further investigated the effect of WSZG on the gene expression levels of bone metastatic tissues from a breast cancer xenograft model. Real-time PCR analysis showed that the expression levels of the four genes in bone metastatic tissues from model B mice were overexpressed greater than 12-20-fold in bone metastatic tissues from nor- Effect of WSZG on CCL5/CCR5 and IL-17B/IL-17BR protein expres sion in bone metastatic tissues Immunohistochemical assay As shown in Figure 5 , the protein levels of CCL5/CCR5 and IL-17B/IL-17BR were significantly overexpressed in breast cancer bone metastatic regions relative to those in normal bone tissues. Furthermore, co-injection of MDA-MB-231BO cancer cells with BMSCs slightly increased the expression of the four proteins compared with the injection of MDA-MB-231BO cells alone. After treatment with WSZG and ZA, these proteins expression decreased steadily. Consistent with the IHC stain, the IHC indexes of CCL5/CCR5 and IL-17B/IL-17BR in the model A and model B groups were considerably higher than those in the normal group (P<0.05 or P<0.01). Compared with the model B group, the IHC index of all proteins significantly decreased in the WSZG (6.50 and 13.0 g/kg) and ZA groups (P<0.05 or P<0.01). The IHC index of CCL5 and IL-17B was also significantly reversed in the WSZG group (3.25 g/kg; P<0.01). In addition, significant differences were observed in the IHC indexes of CCR5 and IL-17B between the WSZGtreated groups and the model A group (P<0.01). 
Western blotting analysis
We further investigated the protein expression levels of CCL5/CCR5 and IL-17B/IL-17BR associated with the interaction between BMSCs and breast cancer cells in bone metastatic tissues through Western blotting. Consistent with the results of the IHC assay, a remarkable increase in the four proteins levels was observed in the bone metastasis tissues from model B mice (Figure 6A ; P<0.01 vs normal mice). Compared to the model B group, WSZG (6.50 and 13.0 g/kg) treatment significantly inhibited the expression levels of the four proteins in bone metastasis tissues. The protein inhibition was 42.3%-43.1% in CCL5, 46.8%-58.2% in CCR5, 73.8%-77.3% in IL-17B, and 44.2%-52.7% in IL-17BR proteins ( Figure 6B ; P<0.05 or P<0.01). Similarly, ZA also significantly suppressed the expression of these proteins (P<0.01).
Discussion
It has been reported that human BMSCs play a fundamental role in breast cancer pathogenesis [20] [21] [22] . BMSCs are recruited to the stroma of the primary tumor site, where they might facilitate breast cancer cell invasion and distant metastasis [23] . Our previous data have shown that WSZG exerted an inhibitory effect on BMSC-induced MDA-MB-231BO breast cancer cell migration in vitro [10] . However, the anti-metastatic efficacy of WSZG in vivo is unclear. In the current study, we further investigated the potential effect of this formula on a mouse model of bone metastasis mediated by the interaction between BMSCs and breast cancer cells (BCCs). In our xenograft model, bioluminescent signals were clearly visible in the skeleton five weeks after the initial injection of tumor cells. Bone lesions were further confirmed by micro-CT and histological analysis. The results showed that MDA-MB-231BO BCCs co-injected with BMSCs at a ratio of 1:1 caused a much higher frequency of bone metastasis and tumor burden compared to BCCs injected alone. However, WSZG treatment (6.5 and 13.0 g/kg) for 4 weeks significantly reduced the incidence and intensity of BCC metastasis in the co-injection model. Importantly, WSZG could also effectively prevent bone lesions by suppressing osteoclast formation and tumor cell infiltration. In addition, we have previously reported a significant decrease in the number of bone metastatic sites and in the extent of bone destruction following administration of WSZG (7.5 and 15 g/kg) in the mono-injection model [6] . Therefore, it has been postulated that WSZG might directly act on BCCs to inhibit metastasis to bone, or indirectly via weakening the interaction of cancer cells with BMSCs.
In multiple studies, the chemokine C-C motif ligand 5 (CCL5) and chemokine receptor (CCR5) axis has been indi- [24, 25] . CCL5 is not only highly expressed by BCCs at the primary tumor and metastatic sites [26, 27] but also expressed by stromal and immune cells, such as BMSCs, tumor-associated macrophages [28] , myeloid-derived suppressor cells, and T-regulatory cells [29] , in the tumor microenvironment. BCCs stimulate CCL5 secretion by BMSCs or other cells, and then CCL5 acts by binding with the highest affinity to CCR5 in BCCs to enhance their motility, invasion, and metastasis to distant organs [24, 30] . The potential mechanisms for these actions include promoting the recruitment of additional stromal cells, participating in the immune response, activating matrix metalloproteinase, etc [31] . Additionally, recent studies have reported that interleukin 17 (IL-17) family members and their receptors are closely correlated to tumor malignancy and progression [32] [33] [34] . As a pro-inflammatory cytokine, IL-17B is mainly produced by helper T (Th) 17 cells, innate and adaptive immune cells, and BMSCs [35] [36] [37] [38] , and its receptor (IL-17BR) is present on tumor cells. Activated IL-17B/IL-17BR signaling can increase the tumorigenic and metastatic abilities of tumor cells via stimulating the secretion of chemokines or enhancing inflammatory activities [34, 39] . Notably, a previous study also found that IL-17B/IL-17BR signaling could promote bone metastasis by mediating the interaction of BMSCs with BCCs [3] . Taken together, CCL5/CCR5 and IL-17B/IL-17BR may represent important biomarkers and therapeutic targets for breast cancer progression.
Therefore, we further assessed whether the anti-metastatic effect of WSZG was indirectly dependent on the interaction [10] . The inhibition of the metastatic ability of MDA-MB-231BO cells by WSZG treatment, at least partially, was dependent on the CCL5/CCR5 and IL-17B/IL-17BR axis.
In summary, WSZG treatment efficiently reduced the risk of bone metastases and the bone lesions in a mouse xenograft model of breast cancer. Its therapeutic effect was partially achieved by impairing the interaction of BMSCs with BCCs in the tumor microenvironment. Therefore, our findings suggest that WSZG may serve as a potential anti-metastatic agent for breast cancer. The cross-talk between BMSCs and tumor cells mediated by different signaling pathways also needs further exploration in the future.
